Application of Flow Cytometry to Platelet Disorders

Flow cytometry is a powerful and versatile tool that can be used to yield definitive information regarding the phenotypic status of platelets. The method provides a quantitative assessment of the physical and antigenic properties of platelets (e.g., surface expression of receptors, bound ligands, components of granules, or interactions of platelets with other platelets, other blood cells, or components of the plasma coagulation system), thereby facilitating the diagnosis of inherited or acquired platelet disorders (e.g., Bernard-Soulier syndrome, Glanzmann thrombasthenia, storage pool disease), the pathological activation of platelets (e.g., in the setting of acute coronary syndromes, cerebrovascular ischemia, peripheral vascular disease, cardiopulmonary bypass), and changes in the ability of platelets to activate via specific stimuli (e.g., efficacy of antiplatelet therapies). Accordingly, this review summarizes the key technical and methodologic components of flow cytometric analysis of platelets, as well as specific examples of its application to diagnosis and patient care.

KEYWORDS

Platelets - flow cytometry - platelet disorders - platelet activation - acute coronary syndromes

REFERENCES

• 1 Michelson A D, Barnard M R, Krueger L A et al.. Flow cytometry. In: Michelson AD Platelets San Diego, CA; Academic Press 2002: 297-315
• 2 Shapiro H M. Practical Flow Cytometry. 4th ed. New York; Wiley-Liss 2003
• 3 Michelson A D, Barnard M R, Hechtman H B et al.. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function.  Proc Natl Acad Sci USA. 1996;  93 11877-11882
• 4 Moritz A, Walcheck B K, Deye J, Weiss D J. Effects of short-term racing activity on platelet and neutrophil activation in dogs.  Am J Vet Res. 2003;  64 855-859
• 5 Boudreaux M K, Panangala V S, Bourne C. A platelet activation-specific monoclonal antibody that recognizes a receptor-induced binding site on canine fibrinogen.  Vet Pathol. 1996;  33 419-427
• 6 Michelson A D, Benoit S E, Kroll M H et al.. The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible.  Blood. 1994;  83 3562-3573
• 7 Shattil S J, Hoxie J A, Cunningham M, Brass L F. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation.  J Biol Chem. 1985;  260 11107-11114
• 8 Michelson A D, Furman M I. Laboratory markers of platelet activation and their clinical significance.  Curr Opin Hematol. 1999;  6 342-348
• 9 Barnard M R, Krueger L A, Frelinger A L et al.. Whole blood analysis of leukocyte-platelet aggregates. In: Robinson JP, Darzynkiewicz Z, Dean PN Current Protocols in Cytometry New York; John Wiley & Sons 2003 06.15.01-06: 15.08
• 10 Shattil S J, Cunningham M, Hoxie J A. Detection of activated platelets in whole blood using activation-dependant antibodies and flow cytometry.  Blood. 1987;  70 307-315
• 11 Serebruany V L, Kereiakes D J, Dalesandro M R, Gurbel P A. The flow cytometer model markedly affects measurement of ex vivo whole blood platelet-bound P-selectin expression in patients with chest pain: are we comparing apples with oranges.  Thromb Res. 1999;  96 51-56
• 12 Abrams C, Shattil S J. Immunological detection of activated platelets in clinical disorders.  Thromb Haemost. 1991;  65 467-473
• 13 Michelson A D. Flow cytometry: a clinical test of platelet function.  Blood. 1996;  87 4925-4936
• 14 Rajasekhar D, Barnard M R, Bednarek F J, Michelson A D. Platelet hyporeactivity in very low birth weight neonates.  Thromb Haemost. 1997;  77 1002-1007
• 15 Michelson A D, Barnard M R, Krueger L A et al.. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction.  Circulation. 2001;  104 1533-1537
• 16 Furman M I, Krueger L A, Frelinger III A L et al.. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.  Thromb Haemost. 2000;  84 492-498
• 17 Krueger L A, Barnard M R, Frelinger III A L et al.. Immunophenotypic analysis of platelets. In: Robinson JP, Darzynkiewicz Z, Dean PN Current Protocols in Cytometry. New York; John Wiley & Sons, Inc 2002: 06.10.01-06.10.17
• 18 Phillips D R, Teng W, Arfsten A et al.. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.  Circulation. 1997;  96 1488-1494
• 19 Ginsberg M H, Lightsey A, Kunicki T J et al.. Divalent cation regulation of the surface orientation of platelet membrane glycoprotein IIb.  J Clin Invest. 1986;  78 1103-1111
• 20 Kozek-Langenecker S A, Mohammad S F, Masaki T et al.. The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry.  Anesth Analg. 2000;  90 808-812
• 21 Filip D J, Aster R H. Relative hemostatic effectiveness of platelets stored at 4° and 22°C.  J Lab Clin Med. 1978;  91 618-624
• 22 Kuo Y R, Jeng S F, Wang F S et al.. Platelet glycoprotein IIb/IIIa receptor antagonist (abciximab) inhibited platelet activation and promoted skin flap survival after ischemia/reperfusion injury.  J Surg Res. 2002;  107 50-55
• 23 Furman M I, Kereiakes D J, Krueger L A et al.. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.  Am Heart J. 2003;  145
• 24 Furman M I, Kereiakes D J, Krueger L A et al.. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.  Am Heart J. 2001;  142 790-798
• 25 Michelson A D, Barnard M R, Krueger L A et al.. Evaluation of platelet function by flow cytometry.  Methods. 2000;  21 259-270
• 26 Wall J E, Buijs-Wilts M, Arnold J T et al.. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents.  Br J Haematol. 1995;  89 380-385
• 27 Gordon N, Thom J, Cole C, Baker R. Rapid detection of hereditary and acquired storage pool deficiency by flow cytometry.  Br J Haematol. 1995;  89 117-123
• 28 Michelson A D. Flow cytometric analysis of platelet surface glycoproteins: phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia.  J Lab Clin Med. 1987;  110 346-354
• 29 Jennings L K, Ashmun R A, Wang W C, Dockter M E. Analysis of human platelet glycoproteins IIb-IIIa and Glanzmann's thrombasthenia in whole blood by flow cytometry.  Blood. 1986;  68 173-179
• 30 Furman M I, Benoit S E, Barnard M R et al.. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.  J Am Coll Cardiol. 1998;  31 352-358
• 31 Ott I, Neumann F J, Gawaz M et al.. Increased neutrophil-platelet adhesion in patients with unstable angina.  Circulation. 1996;  94 1239-1246
• 32 Kienast J, Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: A diagnostic aid in the evaluation of thrombocytopenic disorders.  Blood. 1990;  75 116-121
• 33 Matic G B, Chapman E S, Zaiss M et al.. Whole blood analysis of reticulated platelets: improvements of detection and assay stability.  Cytometry. 1998;  34 229-234
• 34 Gawaz M, Seyfarth M, Muller I et al.. Comparisons of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent replacement.  Am J Cardiol. 2001;  87 332-336
• 35 Warkentin T E, Hayward C P, Boshkov L K et al.. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.  Blood. 1994;  84 3691-3699
• 36 Nurden A T, Nurden P. Inherited disorders of platelet function. In: Michelson AD Platelets San Diego; Academic Press 2002: 681-700
• 37 Lopez J A, Berndt M C. The GPIb-IX-V complex. In: Michelson AD Platelets San Diego; Academic Press 2002: 85-104
• 38 Rao A K, Gabbeta J. Congenital disorders of platelet signal transduction.  Arterioscl Thromb Vasc Biol. 2000;  20 285-289
• 39 Reed G L. Platelet secretion. In: Michelson AD Platelets San Diego; Academic Press 2002: 181-195
• 40 Gawaz M P, Bogner C, Gurland H J. Flow-cytometric analysis of mepacrine-labelled platelets in patients with end-stage renal failure.  Haemostasis. 1993;  23 284-292
• 41 Fabris F, Scandellari R, Randi M L et al.. Attempt to improve the diagnosis of immune thrombocytopenia by combined use of two different platelet autoantibodies assays (PAIgG and MACE).  Haematologica. 2002;  87 1046-1052
• 42 Lindahl T L, Fagerberg I H, Larsson A. A new flow cytometric method for measurement of von Willebrand factor activity.  Scand J Clin Lab Invest. 2003;  63 217-223
• 43 Heeschen C, Hamm C W, Zeiher A M. Soluble CD40 ligand in acute coronary syndromes.  N Engl J Med. 2003;  348 1104-1111
• 44 Kamath S, Blann A D, Caine G J et al.. Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation.  Stroke. 2002;  33 1237-1242
• 45 Varo N, de Lemos J A, Libby P et al.. Soluble CD40L: Risk prediction after acute coronary syndromes.  Circulation. 2003;  108 1049-1052
• 46 Michelson A D, Ellis P A, Barnard M R et al.. Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, ADP or an in vivo wound.  Blood. 1991;  77 770-779
• 47 Faraday N, Goldschmidt-Clermont P, Dise K, Bray P F. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry.  J Lab Clin Med. 1994;  123 728-740
• 48 Frelinger III A L, Lam S CT, Plow E F et al.. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion.  J Biol Chem. 1988;  263 12397-12402
• 49 Kouns W C, Kirchhofer D, Hadvary P et al.. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor.  Blood. 1992;  80 2539-2547
• 50 Zamarron C, Ginsberg M H, Plow E F. Monoclonal antibodies specific for a conformationally altered state of fibrinogen.  Thromb Haemost. 1990;  64 41-46
• 51 Heilmann E, Hynes L A, Burstein S A et al.. Fluorescein derivatization of fibrinogen for flow cytometric analysis of fibrinogen binding to platelets.  Cytometry. 1994;  17 287-293
• 52 McEver R P. P-Selectin/PSGL-1 and other interactions between platelets, leukocytes, and endothelium. In: Michelson AD Platelets San Diego; Academic Press 2002: 139-155
• 53 Hsu-Lin S C, Berman C L, Furie B C et al.. A platelet membrane protein expressed during platelet activation and secretion: studies using a monoclonal antibody specific for thrombin-activated platelets.  J Biol Chem. 1984;  259 9121-9126
• 54 Stenberg P E, McEver R P, Shuman M A et al.. A platelet alpha-granule membrane protein (GMP-140) is expressed on the platelet membrane after activation.  J Cell Biol. 1985;  101 880-886
• 55 Ruf A, Patscheke H. Flow cytometric detection of activated platelets: comparison of determining shape change, fibrinogen binding, and P-selectin expression.  Semin Thromb Hemost. 1995;  21 146-151
• 56 Metzelaar M J, Wijngaard P L, Peters P J et al.. CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells.  J Biol Chem. 1991;  266 3239-3245
• 57 Furman M I, Barnard M R, Krueger L A et al.. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction.  J Am Coll Cardiol. 2001;  38 1002-1006
• 58 Peyton B D, Rohrer M J, Furman M I et al.. Patients with venous stasis ulceration have increased monocyte-platelet aggregation.  J Vasc Surg. 1998;  27 1109-1115
• 59 Sims P J, Faioni E M, Wiedmer T, Shattil S J. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity.  J Biol Chem. 1988;  263 18205-18212
• 60 Nieuwland R, Sturk A. Platelet-derived microparticles. In: Michelson AD Platelets San Diego; Academic Press 2002: 255-265
• 61 Sims P J, Wiedmer T, Esmon C T et al.. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity.  J Biol Chem. 1989;  264 17049-17057
• 62 Michelson A D, Rajasekhar D, Bednarek F J, Barnard M R. Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults.  Thromb Haemost. 2000;  84 689-694
• 63 Ault K A, Rinder H M, Mitchell J G et al.. Correlated measurement of platelet release and aggregation in whole blood.  Cytometry. 1989;  10 448-455
• 64 Flores N A, Sheridan D J. The pathophysiological role of platelets during myocardial ischaemia.  Cardiovasc Res. 1994;  28 295-302
• 65 Fuster V, Badimon L, Badimon J J, Chesebro J H. The pathogenesis of coronary artery disease and acute coronary syndromes.  N Engl J Med. 1992;  326 310-318
• 66 deWood M A, Spores J, Notske R et al.. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.  N Engl J Med. 1980;  303 897-902
• 67 Antiplatelet Trialists' Collaboration . Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.  BMJ. 1994;  308 81-106
• 68 Antiplatelet Trialists' Collaboration . Collaborative overview of randomised trials of antiplatelet therapy. III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients.  BMJ. 1994;  308 235-246
• 69 Peripheral Arterial Diseases Antiplatelet Consensus Group . Antiplatelet therapy in peripheral arterial disease. Consensus statement.  Eur J Vasc Endovasc Surg. 2003;  26 1-16
• 70 Mehta S R, Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.  J Am Coll Cardiol. 2003;  41 79S-88S
• 71 Koyama H, Maeno T, Fukumoto S et al.. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans.  Circulation. 2003;  108 524-529
• 72 Coulter S A, Cannon C P, Ault K A et al.. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.  Circulation. 2000;  101 2690-2695
• 73 Schultheiss H P, Tschoepe D, Esser J et al.. Large platelets continue to circulate in an activated states after myocardial infarction.  Eur J Clin Invest. 1994;  24 243-247
• 74 Lee Y, Lee W H, Lee S C et al.. CD40L activation in circulating platelets in patients with acute coronary syndrome.  Cardiology. 1999;  92 11-16
• 75 Scharf R E, Tomer A, Marzec U M et al.. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection.  Arterioscl Thromb. 1992;  12 1475-1487
• 76 Gurbel P A, Kereiakes D J, Dalesandro M R et al.. Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department.  Am Heart J. 2000;  139 320-328
• 77 Langford E J, Wainwright R J, Martin J F. Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors.  Arterioscl Thromb Vasc Biol. 1996;  16 51-55
• 78 Ault K A, Cannon C P, Mitchell J G et al.. Platelet activation in patients after an acute coronary syndrome L results from the TIMI-12 trial. Thrombolysis in myocardial infarction.  J Am Coll Cardiol. 1999;  33 634-639
• 79 Gawaz M, Neumann F J, Ott I et al.. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy.  Circulation. 1996;  94 279-285
• 80 Neumann F J, Gawaz M, Dickfeld T et al.. Antiplatelet effect of ticlopidine after coronary stenting.  J Am Coll Cardiol. 1997;  29 1515-1519
• 81 Tschoepe D, Schultheiss H P, Kolarov P et al.. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA.  Circulation. 1993;  88 37-42
• 82 Ginsberg M H, Frelinger III A L, Lam S CT et al.. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies.  Blood. 1990;  76 2017-2023
• 83 Fateh-Moghadam S, Bocksch W, Ruf A et al.. Changes in surface expression of platelet membrane glycoproteins and progression of heart transplant vasculopathy.  Circulation. 2000;  102 890-897
• 84 Mallat Z, Benamer H, Hugel B et al.. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.  Circulation. 2000;  101 841-843
• 85 Vidal C, Spaulding C, Picard F et al.. Flow cytometry detection of platelet procoagulation activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation.  Thromb Haemost. 2001;  86 784-790
• 86 Gawaz M, Reininger A, Neumann F J. Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease. Effects of intravenous magnesium.  Thromb Res. 1996;  83 341-349
• 87 Neumann F J, Marx N, Gawaz M et al.. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets.  Circulation. 1997;  95 2387-2394
• 88 Katopodis J N, Kolodny L, Jy W et al.. Platelet microparticles and calcium homeostasis in acute coronary ischemias.  Am J Hematol. 1997;  54 95-101
• 89 Mickelson J K, Lakkis N M, Villarreal-Levy G et al.. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?.  J Am Coll Cardiol. 1996;  28 345-353
• 90 Grau A J, Ruf A, Vogt A et al.. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia.  Thromb Haemost. 1998;  80 298-301
• 91 Cherian P, Hankey G J, Eikelboom J W et al.. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes.  Stroke. 2003;  34 2132-2137
• 92 Minamino T, Kitakaze M, Sanada S et al.. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide.  Circulation. 1998;  98 1721-1727
• 93 Meiklejohn D J, Vickers M A, Morrison E R et al.. In vivo platelet activation in atherothrombotic stroke is not determined by polymorphisms of human platelet glycoprotein IIIa or Ib.  Br J Haematol. 2001;  112 621-631
• 94 Zeiger F, Stephan S, Hoheisel G et al.. P-selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease.  Blood Coagul Fibrinolysis. 2000;  11 723-728
• 95 Powell C C, Rohrer M J, Barnard M R et al.. Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation.  J Vasc Surg. 1999;  30 844-851
• 96 Tschoepe D, Roesen P, Esser J et al.. Large platelets circulate in an active state in diabetes mellitus.  Semin Thromb Hemost. 1991;  17 433-438
• 97 Tschoepe D, Menart-Houtermans B. Diabetes Mellitus. In: Michelson AD Platelets San Diego; Academic Press 2002: 435-445
• 98 Janes S L, Goodall A H. Flow cytometric detection of circulating activated platelets and platelet hyper-responsiveness in pre-eclampsia and pregnancy.  Clin Sci. 1994;  86 731-739
• 99 Klein B, Farildi A, Amo-Takyi B K et al.. Neonatal platelet activation in preeclampsia.  Clin Appl Thromb Hemost. 2001;  7 29-32
• 100 Kawabata K, Nakai S, Miwa M et al.. Platelet GPIIb/IIIa is activated and platelet-leukocyte coaggregates formed in vivo during hemodialysis.  Nephron. 2002;  90 391-400
• 101 Ando M, Iwata A, Ozeki Y et al.. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients.  Kidney Int. 2002;  62 1757-1763
• 102 Russworm S, Vickers J, Meier-Hellmann A et al.. Platelet and leukocyte activation correlate with the severity of septic organ dysfunction.  Shock. 2002;  17 263-268
• 103 Joop K, Berckmans R J, Nieuwland R et al.. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms.  Thromb Haemost. 2001;  85 810-820
• 104 Villmow T, Kemkes-Matthes B, Matzdorff A C. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes.  Thromb Res. 2002;  108 139-145
• 105 Sevush S, Jy W, Horstman L L et al.. Platelet activation in Alzheimer disease.  Arch Neurol. 1998;  55 530-536
• 106 Zilla P, Fasol R, Groscurth P et al.. Blood platelets in cardiopulmonary bypass operations.  J Thorac Cardiovasc Surg. 1989;  97 379-388
• 107 Smith B R, Rinder H M, Rinder C S. Cardiopulmonary bypass. In: Michelson AD Platelets San Diego; Academic Press 2002: 27-741
• 108 Rinder C S, Gaal D, Student L A, Smith B R. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass.  J Thorac Cardiovasc Surg. 1994;  107 280-288
• 109 Harker L A, Malpass T W, Branson H E et al.. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha granule release.  Blood. 1980;  56 824-828
• 110 Michelson A D. The hemostatic defect of cardiopulmonary Bypass. In: Jones R, Elliott M Cardiopulmonary bypass in Neonates, Infants and Young Children. Oxford; Butterworth-Heinemann 1994
• 111 Warkentin T E, Chong B H, Greinacher A. Heparin induced thrombocytopenia: toward consensus.  Thromb Haemost. 1998;  79 1-7
• 112 Wahba A, Rothe G, Lodes H et al.. Effect of extracorporeal circulation and heparin on the phenotype of platelet surface antigens following heart surgery.  Thromb Res. 2000;  97 379-386
• 113 Ellison N, Edmunds L H, Colman R W. Platelet aggregation following heparin and protamine administration.  Anesthesiology. 1978;  48 65-68
• 114 Morse D S, Adams D, Magnani B. Platelet and neutrophil activation during cardiac surgical procedures: impact of cardiopulmonary bypass.  Ann Thorac Surg. 1998;  65 691-695
• 115 Musial J, Niewiarowski S, Hershock D et al.. Loss of fibrinogen receptors from the platelet surface during simulated extracorporeal circulation.  J Lab Clin Med. 1985;  105 514-522
• 116 Salzman E W, Lindon J, Brier D, Merrill E W. Surface-induced platelet adhesion, aggregation and release.  Ann N Y Acad Sci. 1977;  283 114-127
• 117 Wenger W K, Lukasiewicz H, Mikuta B S et al.. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass.  J Thorac Cardiovasc Surg. 1989;  97 235-239
• 118 Kestin A S, Valeri C R, Khuri S F et al.. The platelet function defect of cardiopulmonary bypass.  Blood. 1993;  82 107-117
• 119 Rinder C S, Mathew J, Rinder J et al.. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass.  Anesthesiology. 1991;  75 563-570
• 120 Khuri S F, Michelson A D, Valeri C R. The effects of cardiopulmonary bypass on hemostasis. In: Loscabo J, Schaferai AI Thrombosis & Hemorrhage Cambridge; Blackwell Science 1993: 1051-1073
• 121 Linden M D, Erber W N, Schneider M. Heparin management during cardiopulmonary bypass.  J Cardiovasc Surg. 2001;  42 431-433
• 122 Ng K FJ, Lam C CK, Chan L C. In vivo effect of haemodilution with saline on coagulation: a randomized controlled trial.  Br J Anaesth. 2002;  88 475-480
• 123 Michelson A D, Macgregor H, Barnard M R et al.. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro.  Thromb Haemost. 1994;  71 633-640
• 124 Ferraris V A, Ferraris S P, Joseph O et al.. Aspirin and postoperative bleeding after coronary artery bypass grafting.  Ann Surg. 2002;  235 820-827
• 125 Smith S C, Dove J T, Jacobs A K et al.. ACC/AHA guidelines intervention: Executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise The 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty).  Circulation. 2001;  104 3019-3043
• 126 Konstantopoulos K, Kamat S G, Schafer A I et al.. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment C7E3 Fab, in patients undergoing coronary angioplasty.  Circulation. 1995;  91 1427-1431
• 127 Gawaz M, Ruf A, Neumann F J et al.. Effect of glycoprotein IIB-IIIA receptor antagonism on platelet membrane glycoproteins after coronary stent placement.  Thromb Haemost. 1998;  80 994-1001
• 128 Quinn M, Deering A, Stewart M et al.. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antigens.  Circulation. 1999;  99 2231-2238
• 129 Hezard N, Metz D, Nazeyrollas P et al.. Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA.  Thromb Haemost. 1999;  81 869-873
• 130 Tsao P W, Bozarth J M, Jackson S A et al.. Platelet GPIIb/IIIa receptor occupancy studies using a novel fluoresceinated cyclic Arg-Gly-Asp peptide.  Thromb Res. 1995;  77 543-556
• 131 Wittig K, Rothe G, Schmitz G. Inhibition of fibrinogen binding and surface recruitment of GPIIb/IIIa as dose-dependent effects of the RGD-mimetic MK-852.  Thromb Haemost. 1998;  79 625-630
• 132 Peter K, Kohler B, Straub A et al.. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.  Circulation. 2000;  102 1490-1496
• 133 Jennings L K, White M M. Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors.  Am Heart J. 1998;  135 S179-S183
• 134 ISIS-2 Collaborative Group . Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction:ISIS-2.  Lancet. 1998;  2 349-360
• 135 Lewis H D, Davis J W, Archibald D G et al.. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina.  N Engl J Med. 1983;  309 396-403
• 136 Malinin A I, Atar D, Callahan K P et al.. Effect of a single dose of aspirin on platelets in humans with multiple risk factors for coronary artery disease.  Eur J Pharmacol. 2003;  462 139-143
• 137 Sane D C, McKee S A, Malinin A I, Serebruany V L. Frequency of aspirin resistance in patients with congestive heart failure with antecedant aspirin.  Am J Cardiol. 2002;  90 893-895
• 138 Frelinger III A L, Marchese P J, Barnard M R et al.. Flow cytometric assessment of aspirin and NSAID effects on platelet function and leukocyte-platelet aggregation.  Blood. 2002;  100 704A
• 139 Hollopeter G, Jantzen H-M, Vincent D et al.. Identification of the platelet ADP receptor targeted by antithrombotic drugs.  Nature. 2001;  409 202-207
• 140 The CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  Lancet. 1996;  348 1329-1339
• 141 Klinkhardt U, Bauersachs R, Adams J et al.. Clopidogrel but not aspirin reduced P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.  Clin Pharmacol Ther. 2003;  73 232-241
• 142 Storey R F, Judge H M, Wilcox R G, Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y 12 receptor antagonist AR-C69931MX but not aspirin.  Thromb Haemost. 2002;  88 488-494
• 143 Klinkhardt U, Graff J, Graff J. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model.  Clin Pharmacol Ther. 2002;  71 176-185
• 144 Keha D, Thieme A, Kurer I et al.. Inactivation of platelet glycoprotein IIb/IIIa receptor by nitric oxide donor 3-morpholino-sydnonimine.  Blood Coagul Fibrinolysis. 2003;  14 327-334
• 145 Kozek-Langenecker S A, Mohammad S F, Masaki T et al.. The effects of aprotinin on platelets in vitro using whole blood flow cytometry.  Anesth Analg. 2000;  90 12-16
• 146 Hu H, Hjemdahl P, Li N. Effects of insulin on platelet and leukocyte activity in whole blood.  Thromb Res. 2002;  107 209-215
• 147 Murphy K J, Chronopoulos A K, Singh I et al.. Dietary Flavanols and procyanidin oligomers from cocoa (Theobroma cacao) inhibit platelet function.  Am J Clin Nutr. 2003;  77 1466-1473
• 148 Heesch C M, Wilhelm C R, Ristich J et al.. Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans.  Heart. 2000;  83 688-695
• 149 de Rossi L, Wessiepe M, Buhre W et al.. Effect of propofol on adhesion of activated platelets to leukocytes in human whole blood.  Intensive Care Med. 2003;  29 1157-1163
• 150 Horn N A, de Rossi L, Robitzsch T et al.. The effects of sevoflurane and desflurane in vitro on platelet-leukocyte adhesion in whole blood.  Anaesthesia. 2003;  58 312-319
• 151 Chong B H. Heparin-induced thrombocytopenia. In: Michelson AD Platelets San Diego; Academic Press 2002: 571-591
• 152 Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia.  Br J Haematol. 1997;  98 648-656
• 153 Romp K G, PeteRs W P, Hoffman M. Reticulated platelet counts in patients undergoing autologous bone marrow transplantation: an aid in assessing marrow recovery.  Am J Hematol. 1994;  46 319-324
• 154 Rinder H M, Schuster J E, Rinder C S et al.. Correlation of thrombosis with increased platelet turnover in thrombocytosis.  Blood. 1998;  91 1288-1294